secwatch.observer — SEC 8-K summary
======================================

Issuer:     LABCORP HOLDINGS INC. (LH)
CIK:        0000920148
Form:       8-K
Filed at:   2025-11-24T23:59:59+00:00
Accession:  0000920148-25-000111
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Labcorp appoints Novartis U.S. President Victor Bulto to Board of Directors
---------------------------------------------------------------------------

- Victor Bulto appointed to Labcorp's Board effective December 1, 2025; he is President of Novartis U.S. and member of Novartis Executive Committee.
- Bulto brings 25 years of healthcare experience and oversees Novartis' $20B+ U.S. business across oncology, immunology, neuroscience, and cardiovascular-renal-metabolic areas.
- CEO Adam Schechter stated Bulto's expertise in therapeutic areas and transformation will support Labcorp's innovation and long-term growth strategy.
- Bulto will receive compensation consistent with Labcorp's director compensation program as described in the April 4, 2025 proxy statement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/920148/000092014825000111/0000920148-25-000111-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/920148/000092014825000111/lh-20251120.htm
  HTML page:      https://secwatch.observer/filing/0000920148-25-000111

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer